Literature DB >> 22012661

The use of plerixafor in harvesting autologous stem cells in the pediatric setting.

Kim Vettenranta1, Merja Möttönen, Pekka Riikonen.   

Abstract

The mobilization of stem cells using the standard approach, chemotherapy and G-CSF, may not be successful in all cases heavily pretreated. Plerixafor (AMD3100) has emerged as a viable option in attempts to mobilize stem cells among these patients. The use of plerixafor in the adult setting has been established, but data on pediatric use is scarce. We report on the use of plerixafor in eight pediatric cases either as add-on to chemotherapy plus G-CSF or in remobilization.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 22012661     DOI: 10.1002/pbc.23361

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  4 in total

Review 1.  Successful mobilisation of peripheral blood stem cells in children using plerixafor: a case report and review of the literature.

Authors:  Angelo Gardellini; Aleksandra Babic; Federica Gigli; Sarah Jane Liptrott; Giovanni Martinelli; Daniele Laszlo
Journal:  Blood Transfus       Date:  2012-10-10       Impact factor: 3.443

2.  Efficacy of plerixafor in children with malignant tumors failing to mobilize a sufficient number of hematopoietic progenitors with G-CSF.

Authors:  A A Maschan; D N Balashov; E E Kurnikova; P E Trakhtman; E V Boyakova; E V Skorobogatova; G A Novichkova; M A Maschan
Journal:  Bone Marrow Transplant       Date:  2015-04-27       Impact factor: 5.483

3.  Influence of a dual-injection regimen, plerixafor and CXCR4 on in utero hematopoietic stem cell transplantation and engraftment with use of the sheep model.

Authors:  A Daisy Goodrich; Nicole M Varain; Christine M Jeanblanc; Donna M Colon; Jaehyup Kim; Esmail D Zanjani; Peiman Hematti
Journal:  Cytotherapy       Date:  2014-09       Impact factor: 5.414

4.  Plerixafor stem cell mobilization in Japanese children: A post-marketing study.

Authors:  Hiroaki Goto; Rie Kanamori; Satoshi Nishina; Takashi Seto
Journal:  Pediatr Int       Date:  2022-01       Impact factor: 1.617

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.